Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays

GlobeNewswire May 19, 2020

ProMIS Neurosciences Announces First Quarter 2020 Results

GlobeNewswire May 13, 2020

ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

GlobeNewswire May 12, 2020

ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS

GlobeNewswire May 6, 2020

ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

GlobeNewswire April 30, 2020

ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing

GlobeNewswire April 22, 2020

ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity

GlobeNewswire April 15, 2020

Journal of the American Academy of Neurology Publishes ProMIS Neurosciences' Abstracts on Novel Antibody Candidates

GlobeNewswire April 9, 2020

ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020

GlobeNewswire April 7, 2020

PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

GlobeNewswire March 24, 2020

ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

GlobeNewswire March 18, 2020

ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer's Disease

GlobeNewswire February 26, 2020

ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants

GlobeNewswire February 25, 2020

ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference

GlobeNewswire February 11, 2020

ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference

GlobeNewswire February 6, 2020

ProMIS Neurosciences Data for Alzheimer's Disease Program Targeting Tau Accepted for Presentation at Tau2020

GlobeNewswire January 29, 2020

How to Prosper in Canada’s 2030 Economic Vision

Jonathon Brown January 15, 2020

ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board

GlobeNewswire January 15, 2020

ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum

GlobeNewswire January 9, 2020

ProMIS Neurosciences issues Chairman's Update detailing positive outlook for Alzheimer's disease therapy, pipeline in 2020

GlobeNewswire January 8, 2020